New drug trial aims to slash life-threatening fat levels in rare disease
NCT ID NCT05089084
First seen Feb 04, 2026 · Last updated Apr 14, 2026 · Updated 6 times
Summary
This study is testing an investigational drug called plozasiran (ARO-APOC3) in adults with familial chylomicronemia syndrome (FCS), a rare genetic disorder that causes extremely high and dangerous levels of fat in the blood. The main goal is to see if the drug can safely and effectively lower these fat levels, which could reduce the risk of serious complications like pancreatitis. After an initial 10-month comparison against a placebo, all participants will receive the drug for an additional 2-year period.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL CHYLOMICRONEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Site 1
Boca Raton, Florida, 33434, United States
-
Clinical Site 10
Córdoba, X5003DCE, Argentina
-
Clinical Site 11
Formosa, 3600, Argentina
-
Clinical Site 12
Melbourne, 3081, Australia
-
Clinical Site 13
Nedlands, 6009, Australia
-
Clinical Site 14
Camperdown, New South Wales, 2050, Australia
-
Clinical Site 15
St Leonards, New South Wales, 2065, Australia
-
Clinical Site 16
Melbourne, Victoria, 3004, Australia
-
Clinical Site 17
Graz, 8036, Austria
-
Clinical Site 18
Edegem, 2650, Belgium
-
Clinical Site 19
Ghent, 9000, Belgium
-
Clinical Site 2
Suwanee, Georgia, 30024, United States
-
Clinical Site 20
Leuven, 3000, Belgium
-
Clinical Site 21
Liège, 4000, Belgium
-
Clinical Site 22
London, Ontario, N6A 5B7, Canada
-
Clinical Site 23
Toronto, Ontario, M5G 2C4, Canada
-
Clinical Site 24
Chicoutimi, Quebec, G7H 7K9, Canada
-
Clinical Site 25
Montreal, Quebec, H2W 1R7, Canada
-
Clinical Site 26
Québec, Quebec, G1V 4W2, Canada
-
Clinical Site 27
Zagreb, 10000, Croatia
-
Clinical Site 28
Paris, 75013, France
-
Clinical Site 29
Marseille, Cedez 05, 13385, France
-
Clinical Site 3
Indianapolis, Indiana, 46290, United States
-
Clinical Site 30
Jena, 7740, Germany
-
Clinical Site 31
Leipzig, 4103, Germany
-
Clinical Site 32
Galway, H91 YR71, Ireland
-
Clinical Site 33
Jerusalem, 9112001, Israel
-
Clinical Site 34
Chiba, 260-8677, Japan
-
Clinical Site 35
Ishikawa, 920-8641, Japan
-
Clinical Site 36
Osaka, 598-0048, Japan
-
Clinical Site 37
Tochigi, 329-0498, Japan
-
Clinical Site 38
Tokyo, 113-8655, Japan
-
Clinical Site 39
Tokyo, Japan
-
Clinical Site 4
Elkridge, Maryland, 21075, United States
-
Clinical Site 40
Mexico City, 11650, Mexico
-
Clinical Site 41
Tlalpan, Mexico DF, 14000, Mexico
-
Clinical Site 42
Cuernavaca, Morelos, 62250, Mexico
-
Clinical Site 43
Auckland, 2025, New Zealand
-
Clinical Site 44
Auckland, 1010, New Zealand
-
Clinical Site 45
Christchurch, 8011, New Zealand
-
Clinical Site 46
Muscat, Oman
-
Clinical Site 47
Lodz, 93-338, Poland
-
Clinical Site 48
Belgrade, 11000, Serbia
-
Clinical Site 49
Niš, 18000, Serbia
-
Clinical Site 5
St Louis, Missouri, 63110, United States
-
Clinical Site 50
Singapore, 119074, Singapore
-
Clinical Site 51
Gwangju, 61469, South Korea
-
Clinical Site 52
Seoul, 03080, South Korea
-
Clinical Site 53
A Coruña, 15001, Spain
-
Clinical Site 54
Granada, 18012, Spain
-
Clinical Site 55
Madrid, 28007, Spain
-
Clinical Site 56
Santiago de Compostela, 15706, Spain
-
Clinical Site 57
Izmir, 35100, Turkey (Türkiye)
-
Clinical Site 58
Melikgazi, Kayseri, 38030, Turkey (Türkiye)
-
Clinical Site 6
New York, New York, 10029, United States
-
Clinical Site 7
New York, New York, 10016, United States
-
Clinical Site 8
Austin, Texas, 78731, United States
-
Clinical Site 9
Norfolk, Virginia, 23510, United States
Conditions
Explore the condition pages connected to this study.